Inogen Company Profile (NASDAQ:INGN)

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen, Inc (NASDAQ:INGN) posted its earnings results on Tuesday, May, 9th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.15. The company earned $52.50 million during the quarter, compared to analysts' expectations of $49.06 million. Inogen had a net margin of 9.32% and a return on equity of 11.67%. Inogen's quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.12 EPS. View Inogen's Earnings History.

4 brokers have issued 1-year price targets for Inogen's shares. Their forecasts range from $75.00 to $108.00. On average, they expect Inogen's share price to reach $91.00 in the next year. View Analyst Ratings for Inogen.

Here are some recent quotes from research analysts about Inogen stock:

• 1. According to Zacks Investment Research, "Over the last three months, Inogen outperformed the broader industry in terms of price. However, rental revenue headwinds are a concern, thanks to private insurance rate reductions, higher provisions for rental revenue adjustments and lower net patient additions. Inogen reported a solid first quarter of 2017, beating the Zacks Consensus Estimate on both the counts. Inogen generates a significant portion of its revenues from the International market. Volatility in foreign exchange rate is expected to mar the company’s top line in the coming quarters. Furthermore, the stock looks a bit overvalued at the moment when compared to the market at large. However, Inogen has provided a positive guidance for full-year 2017. The company’s unique direct-to-customer business model, an innovative product line and growing patient base are key catalysts in our view." (7/11/2017)
• 2. Needham & Company LLC analysts commented, "INGN beat consensus revenue, EBITDA, and EPS in 1Q17. Management maintained its 2017 revenue and EBITDA guidance and raised its 2017 net income guidance. The revenue upside was driven by 49% growth in B2B more than offsetting 0% growth in DTC. We think that the strong 84% growth in domestic B2B provides further evidence that home medical equipment companies (HMEs) are increasingly adopting portable oxygen concentrators." (5/10/2017)
• 3. Stifel Nicolaus analysts commented, "Inogen (INGN) reported 4Q16 after the close on February 28, 2017 with results better than our expectations. Revenue, Adjusted-EBITDA, and Net Income all exceeded our expectations. Management slightly raised its recently established 2017 guidance. In our view, INGN has a great longer-term story that should continue to evolve and grow as disruption occurs in the high cost delivery model of oxygen to those that need it. Maintain Hold and adjust target to $65 based on a range of valuation multiples." (3/1/2017)

Some companies that are related to Inogen include ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), AtriCure (ATRC), Intersect ENT (XENT), Meridian Bioscience (VIVO), CryoLife (CRY) and Consort Medical plc (CSRT).

Inogen's management team includes the folowing people:

• Heath Lukatch Ph.D., Independent Chairman of the Board
• Scott Wilkinson, President, Chief Executive Officer, Director
• Alison Bauerlein, Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
• Byron Myers, Executive Vice President of Sales and Marketing
• Matthew Scribner, Executive Vice President - Operations
• Brenton Taylor, Executive Vice President - Engineering
• Benjamin M. Anderson-Ray, Independent Director
• Scott A. Beardsley, Independent Director
• R. Scott Greer, Independent Director
• Raymond O. Huggenberger, Independent Director

Inogen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.56%), Rockefeller Financial Services Inc. (1.51%), Bank of Montreal Can (0.25%), Mitsubishi UFJ Asset Management UK Ltd. (0.10%), Thomson Horstmann & Bryant Inc. (0.07%) and Curbstone Financial Management Corp (0.06%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.

Inogen's stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Thomson Horstmann & Bryant Inc., Curbstone Financial Management Corp and Capstone Asset Management Co.. Company insiders that have sold Inogen stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.

Inogen's stock was purchased by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Asset Management UK Ltd., Rockefeller Financial Services Inc., Aperio Group LLC, Eqis Capital Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Inogen.

Shares of Inogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Inogen stock can currently be purchased for approximately $95.22.